As­traZeneca teams with Benev­o­len­tAI on dis­cov­ery, re­search; Cam­bridge spin­out rais­es seed cash for pro­tein degra­da­tion work

→ Right now the heat is on the Big Phar­ma to tie up with the up­starts of AI to see if they can stream­line the dis­cov­ery and ear­ly-stage de­vel­op­ment process that eats up cash and time. And to­day As­traZeneca jumped in with a deal to al­ly with Benev­o­len­tAI on new drugs for chron­ic kid­ney dis­ease and id­io­path­ic pul­monary fi­bro­sis. “The vast amount of da­ta avail­able to re­search sci­en­tists is grow­ing ex­po­nen­tial­ly each year,” says As­traZeneca R&D leader Mene Pan­ga­los. And now they plan to em­ploy the da­ta on their be­half. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER